Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 72, Issue 9, Pages 2570-2573
Publisher
Oxford University Press (OUP)
Online
2017-05-27
DOI
10.1093/jac/dkx195
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results
- (2016) Celia Oldenbuettel et al. ANTIVIRAL THERAPY
- Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients
- (2016) Lisa K Naeger et al. ANTIVIRAL THERAPY
- Dolutegravir Monotherapy in HIV-Infected Naive Patients With
- (2016) Massimiliano Lanzafame et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression
- (2016) Jhon Rojas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia
- (2016) C. Katlama et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: Table 1.
- (2016) Casper Rokx et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients
- (2016) Jean-Guy Baril et al. PLoS One
- Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients
- (2015) Camelia Gubavu et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
- (2014) Maureen Oliveira et al. AIDS
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
- (2013) Thibault Mesplède et al. Retrovirology
- Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1
- (2012) Marc Nischang et al. PLoS One
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure
- (2009) S. Fransen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation